NCT01827657View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

May 28, 2013

Primary Completion Date

March 20, 2014

Study Completion Date

March 20, 2014

Conditions
Hepatitis C
Interventions
DRUG

GSK2336805

Two 30 mg GSK2336805 tablets for a 60 mg single dose will be administered in this study

Trial Locations (4)

32809

GSK Investigational Site, Orlando

37920

GSK Investigational Site, Knoxville

55404

GSK Investigational Site, Minneapolis

80228

GSK Investigational Site, Lakewood

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY